Aeglea Bio Therapeutics (NASDAQ:AGLE) Upgraded by BidaskClub to Hold

BidaskClub upgraded shares of Aeglea Bio Therapeutics (NASDAQ:AGLE) from a sell rating to a hold rating in a report published on Friday, BidAskClub reports.

A number of other research firms have also commented on AGLE. ValuEngine upgraded Aeglea Bio Therapeutics from a buy rating to a strong-buy rating in a research report on Thursday. HC Wainwright restated a buy rating and set a $20.00 price target on shares of Aeglea Bio Therapeutics in a research report on Monday, June 3rd. Three equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. Aeglea Bio Therapeutics currently has an average rating of Buy and a consensus price target of $14.33.

NASDAQ AGLE traded down $0.06 during trading hours on Friday, reaching $8.94. 127,628 shares of the company’s stock were exchanged, compared to its average volume of 145,049. The company has a market cap of $258.48 million, a PE ratio of -4.20 and a beta of 1.01. Aeglea Bio Therapeutics has a one year low of $5.99 and a one year high of $11.16. The business’s fifty day simple moving average is $6.99.

Aeglea Bio Therapeutics (NASDAQ:AGLE) last released its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.59) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.04). Sell-side analysts anticipate that Aeglea Bio Therapeutics will post -2.14 earnings per share for the current year.

In other news, CEO Anthony G. Quinn acquired 26,592 shares of the firm’s stock in a transaction on Wednesday, May 22nd. The shares were purchased at an average cost of $6.77 per share, for a total transaction of $180,027.84. Following the transaction, the chief executive officer now owns 304,135 shares of the company’s stock, valued at $2,058,993.95. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Anthony G. Quinn acquired 6,218 shares of the firm’s stock in a transaction on Friday, May 17th. The stock was purchased at an average price of $6.65 per share, for a total transaction of $41,349.70. Following the completion of the transaction, the chief executive officer now directly owns 277,152 shares in the company, valued at approximately $1,843,060.80. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 92,177 shares of company stock worth $593,817. 12.60% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. BNP Paribas Arbitrage SA bought a new position in Aeglea Bio Therapeutics in the 1st quarter valued at $32,000. Meeder Asset Management Inc. boosted its position in Aeglea Bio Therapeutics by 38.4% in the 1st quarter. Meeder Asset Management Inc. now owns 7,083 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 1,967 shares during the last quarter. Commonwealth Equity Services LLC bought a new position in Aeglea Bio Therapeutics in the 2nd quarter valued at $68,000. Bank of America Corp DE boosted its position in Aeglea Bio Therapeutics by 299.9% in the 4th quarter. Bank of America Corp DE now owns 17,145 shares of the biotechnology company’s stock valued at $128,000 after buying an additional 12,858 shares during the last quarter. Finally, Millennium Management LLC bought a new position in Aeglea Bio Therapeutics in the 4th quarter valued at $156,000. Hedge funds and other institutional investors own 68.47% of the company’s stock.

Aeglea Bio Therapeutics Company Profile

Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.

See Also: Compound Interest and Why It Matters When Investing

Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.